An observational study in Pulmonary Disease and Pulmonary Rehabilitation, sponsored by Saglik Bilimleri Universitesi. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Saglik Bilimleri Universitesi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Lung Diseases with a site in Turkey — 12 open to participants now, 15 under way, 7 of them phase 3. Lung Diseases · Turkey.
Among the 49 studies in Lung Diseases with a site in Turkey, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2025, is one of 12 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 45th registered.
1,159 studies on the registry are indexed under Lung Diseases; 181 are open to participants now.
Browse Lung Diseases studies →12 of the 49 studies in Lung Diseases with a site in Turkey are open now. Recruiting first, the newest first:
Pfizer · Sites in Turkey, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Turkey, United States, Argentina and 16 more countries
Ages 12+
Eli Lilly and Company · Sites in Turkey, United States, Australia and 26 more countries
Ages 18+
Hacettepe University · Sites in Turkey
Ages 18–45 · Healthy volunteers
Taiho Oncology, Inc. · Sites in Turkey, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 138 Lung Diseases studies recruiting now, 75 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 15 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 384 is above the median of 200 across 315 observational studies indexed under Lung Diseases.
Median enrollment 146 across the 37 interventional studies, 121 across the 12 observational. Of the 31 that completed or were terminated, 10 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 49 have an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi is the lead sponsor of 458 studies on the registry; 124 are open to participants now.
Saglik Bilimleri Universitesi has 3 studies filed under Lung Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Lung Diseases with a site in Turkey that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT05973773Phase 3Taiho Oncology, Inc.REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | 2027-05-27 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 49 studies in Lung Diseases with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PRETTY Study aims to evaluate patient satisfaction with pulmonary rehabilitation (PR) services across Türkiye and to investigate how satisfaction levels are related to the organizational structures and team compositions of the PR programs. This national, multicenter, cross-sectional observational study will also identify structural and organizational factors that may enhance patient-centered care and promote the standardization of PR services.
Group/Cohort 1 (Label): Patient Group Description: Adults with respiratory disease who have completed a PR program and will complete the Patient Satisfaction Questionnaire.
Group/Cohort 2 (Label): Program Coordinator Group Description: Healthcare professionals responsible for PR program coordination who will complete the Institutional Survey Form about organizational and team structures.
Patient Inclusion Criteria:
Patient Exclusion Criteria:
Coordinator Inclusion Criteria:
Coordinator Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with a respiratory disease who have completed a pulmonary rehabilitation (PR) program, regardless of the setting (inpatient, outpatient, or home-based).
Other: Patient Satisfaction Questionnaire
Healthcare professionals (e.g., physiotherapists, pulmonologists, or allied health staff) who are designated as coordinators or key team members responsible for organizing and managing the pulmonary rehabilitation program in their institution.
Other: Institutional Survey on PR Program Structure and Team Composition
An online survey designed to assess patient experiences and satisfaction levels with pulmonary rehabilitation (PR) programs. The questionnaire covers aspects such as accessibility, communication, program structure, perceived outcomes, and overall satisfaction. It is administered via Google Forms and completed voluntarily by patients who have completed a PR program.
A structured online questionnaire completed by the designated PR program coordinator or team member. It includes questions on organizational features of the PR program, such as team composition, session frequency, assessment tools, referral and admission
Patient Satisfaction Questionnaire
An online survey designed to assess patient experiences and satisfaction levels with pulmonary rehabilitation (PR) programs. The questionnaire covers aspects such as accessibility, communication, program structure, perceived outcomes, and overall satisfaction. It is administered via Google Forms and completed voluntarily by patients who have completed a PR program.
Time frame: Within 4 weeks after completion of the pulmonary rehabilitation program
Institutional Survey on PR Program Structure and Team Composition
A structured online questionnaire completed by the designated PR program coordinator or team member. It includes questions on organizational features of the PR program, such as team composition, session frequency, assessment tools, referral and admission criteria, and program setting (inpatient, outpatient, or home-based). This survey aims to document the structural diversity of PR services across different healthcare institutions.
Time frame: Within 4 weeks after completion of the pulmonary rehabilitation program
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
Of 131 non-industry observational studies under Lung Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 22 months is below that.
Counting every sponsor, half of 153 studies reached it within 36 months; a quarter within 15 and three quarters within 84.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →